2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
63
Breast Neoplasms
28
Neoplasms
5
Neoplasm Metastasis
3
Leiomyoma
3
Cardiovascular Diseases
3
Polycystic Ovary Syndrome
2
Neoplasms by Site
2
Endometrial Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Stage II Prostate Adenocarcinoma
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sarcopenia
1
Salivary Gland Neoplasms
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Pelvic Pain
1
Ovarian Neoplasms
1
Osteoporosis
1
Oligometastatic Prostate Carcinoma
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Metastatic Neuroendocrine Prostate Cancer
1
Interventions
Cyclophosphamide
31
Trastuzumab
30
Paclitaxel
28
Docetaxel
22
Taxes
18
Doxorubicin
18
Radiotherapy
15
Lapatinib
15
Capecitabine
14
Bevacizumab
13
Tamoxifen
12
Carboplatin
11
Immunohistochemistry
9
Filgrastim
9
sargramostim
8
Granulocyte-Macrophage Colony-Stimulating Factor
8
Chemotherapy, Adjuvant
8
Biopsy
8
exemestane
7
Vorinostat
7
Magnetic Resonance Spectroscopy
7
Letrozole
7
Immunoenzyme Techniques
7
Gemcitabine
7
Anastrozole
7
Albumin-Bound Paclitaxel
7
pegfilgrastim
6
Neoadjuvant Therapy
6
Goserelin
6
Fluorodeoxyglucose F18
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms, Male
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT01638247
2018-09-19
MALE
GBG Forschungs GmbH
Phase 3
Completed
56 enrolled